

Appl. No. 09/448,378
Amdt. dated April 22, 2004
Response to OA of November 5, 2003

2. Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1-5 (Cancelled)

6. (Previously presented) A method for augmenting an immune response in a patient having a cancerous or neoplastic disease, comprising the steps of administering flt3-ligand to the patient in an amount sufficient to generate an increase in the number of the patient's dendritic cells and administering a tumor antigen to the patient.

7. (Previously presented) A method according to claim 6, further comprising the step of administering one or more of the molecules selected from the group consisting of GM-CSF, IL-4, TNF- α , IL-3, c-kit ligand, and fusions of GM-CSF and IL-3.

8-19 (Cancelled)

20. (Previously presented) A method of treating cancerous or neoplastic disease in a patient in need thereof comprising administering flt3-ligand to the patient in an amount sufficient to enhance the patient's immune response to such disease and administering a tumor antigen to the patient.

21. (Cancelled)

22. (Previously presented) The method of claim 6, wherein the flt3-ligand is human flt3-ligand.

23. (Previously presented) The method of claim 22, wherein the flt3-ligand is soluble human flt3-ligand.

24. (Previously presented) The method of claim 23, wherein the soluble human flt3-ligand is recombinant flt3-ligand.

25. (Withdrawn) The method of claim 24, wherein the soluble human flt3-ligand has an amino acid sequence that is encoded by a polynucleotide sequence that hybridizes under moderately stringent conditions to, and is at least 90% identical to, a nucleic acid that encodes an amino acid sequence selected from the group consisting of amino acids 28 to Xaa

Appl. No. 09/448,378
Amdt. dated April 22, 2004
Response to OA of November 5, 2003

of SEQ ID NO:2 and amino acids 28 to Yaa of SEQ ID NO:1, wherein Xaa is an amino acid from 163 to 231, and Yaa is an amino acid from 160 to 235.

26. *(Previously presented)* The method of claim 24, wherein the soluble human flt3-ligand comprises an amino acid sequence selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:2 and amino acids 28 to Yaa of SEQ ID NO:1, wherein Xaa is an amino acid from 163 to 231, and Yaa is an amino acid from 160 to 235.

27. *(Currently amended)* The method of claim 6, wherein the flt3-ligand comprises has the amino acid sequence of residues 28-163 of SEQ ID NO:2.

28. *(Currently amended)* The method of claim 26, wherein the soluble human flt3-ligand comprises has the amino acid sequence of residues 28-160 of SEQ ID NO:1.

29. *(Currently amended)* The method of claim 6, wherein the flt3-ligand comprises has the amino acid sequence of residues 28-188 of SEQ ID NO:2.

30. *(Currently amended)* The method of claim 26, wherein the soluble human flt3-ligand comprises has the amino acid sequence of residues 28-182 of SEQ ID NO:1.

31. *(Previously presented)* The method of claim 20, wherein the flt3-ligand is human flt3-ligand.

32. *(Previously presented)* The method of claim 31, wherein the flt3-ligand is soluble human flt3-ligand.

33. *(Previously presented)* The method of claim 32, wherein the soluble human flt3-ligand is recombinant flt3-ligand.

34. *(Withdrawn)* The method of claim 33, wherein the soluble human flt3-ligand has an amino acid sequence that is encoded by a polynucleotide sequence that hybridizes under moderately stringent conditions to, and is at least 90% identical to, a nucleic acid that encodes an amino acid sequence selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:2 and amino acids 28 to Yaa of SEQ ID NO:1, wherein Xaa is an amino acid from 163 to 231, and Yaa is an amino acid from 160 to 235.

Appl. No. 09/448,378
Amdt. dated April 22, 2004
Response to OA of November 5, 2003

35. *(Previously presented)* The method of claim 33, wherein the soluble human flt3-ligand comprises an amino acid sequence selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:2 and amino acids 28 to Yaa of SEQ ID NO:1, wherein Xaa is an amino acid from 163 to 231, and Yaa is an amino acid from 160 to 235.
36. *(Currently amended)* The method of claim 20, wherein the flt3-ligand comprises ~~has~~ the amino acid sequence of residues 28-163 of SEQ ID NO:2.
37. *(Currently amended)* The method of claim 35, wherein the soluble human flt3-ligand comprises ~~has~~ the amino acid sequence of residues 28-160 of SEQ ID NO:1.
38. *(Currently amended)* The method of claim 20, wherein the flt3-ligand comprises ~~has~~ the amino acid sequence of residues 28-188 of SEQ ID NO:2.
39. *(Currently amended)* The method of claim 35, wherein the soluble human flt3-ligand comprises ~~has~~ the amino acid sequence of residues 28-182 of SEQ ID NO:1.
40. *(Previously presented)* The method of claim 6 wherein the cancerous disease is a tumor.
41. *(Previously presented)* The method of claim 20 wherein the cancerous disease is a tumor.
42. *(Previously presented)* The method of claim 40 wherein the tumor is a fibrosarcoma.
43. *(Previously presented)* The method of claim 41 wherein the tumor is a fibrosarcoma.
44. *(Previously presented)* The method of claim 6, wherein the tumor antigen is in the form of a tumor cell bearing said tumor antigen.
45. *(Previously presented)* The method of claim 6, wherein the tumor antigen is in the form of an isolated tumor antigen.
46. *(Previously presented)* The method of claim 6, wherein the antigen is administered prior to administering flt3-ligand.
47. *(Previously presented)* The method of claim 6, wherein the antigen is administered concurrently with flt3-ligand.

Appl. No. 09/448,378
Amdt. dated April 22, 2004
Response to OA of November 5, 2003

48. *(Previously presented)* The method of claim 6, wherein the antigen is administered after administering flt3-ligand.
49. *(Previously presented)* The method of claim 20, wherein the tumor antigen is in the form of a tumor cell bearing said tumor antigen.
50. *(Previously presented)* The method of claim 20, wherein the tumor antigen is in the form of an isolated tumor antigen.
51. *(Previously presented)* The method of claim 20, wherein the tumor antigen is administered prior to administering flt3-ligand.
52. *(Previously presented)* The method of claim 20, wherein the tumor antigen is administered concurrently with administering flt3-ligand.
53. *(Previously presented)* The method of claim 20, wherein the tumor antigen is administered after administering flt3-ligand.
54. *(Withdrawn)* A method of treating cancerous or neoplastic disease in a patient in need thereof comprising administering flt3-ligand to the patient, isolating dendritic cells from the patient, exposing the dendritic cells to a tumor antigen, and administering the dendritic cells to the patient.
55. *(Withdrawn)* The method of claim 54, wherein the tumor antigen is in the form of a tumor cell bearing said antigen.
56. *(Withdrawn)* The method of claim 54, wherein the tumor antigen is in the form of an isolated tumor antigen.